* Cyclacel pharmaceuticals reports updated data from dna
damage response program on seliciclib and sapacitabine
combination in patients with solid tumors
The post BRIEF-Cyclacel Pharmaceuticals reports updated data from DNA damage response program on seliciclib, sapacitabine combination appeared first on NASDAQ.